Ultragenyx licenses fatty acid oxidation disorder compound

Baylor Research Institute (Dallas, Texas) granted Orphan disease company Ultragenyx Pharmaceutical Inc. (Novato, Calif.) exclusive, North American rights to develop and commercialize tripheptanoin (UX007), which is in development for long-chain fatty acid oxidation disorders. Ultragenyx has an exclusive option to expand the deal to include worldwide rights. Ultragenyx said the parties are not disclosing financial details. ...